Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04773041 · ClinicalTrials.gov registry record

Dementia With Lewy Bodies - Infinitome

A clinical trial, sponsored by HealthPartners Institute.

Completed
Registry status
91
Enrollment target

NCT04773041 is a clinical trial that has completed, run by HealthPartners Institute. The registered enrollment target is 91 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04773041 has completed, sponsored by HealthPartners Institute.

COMPLETED
Registry status
91 participants
Enrollment target

Study Summary

Dementia with Lewy bodies (DLB) is the second most common cause of dementia and is associated with parkinsonism, hallucinations, and cognitive fluctuations. Diagnosis is often either missed or delayed due to physician lack of familiarity with characteristic features, the inability of structural MRI to detect a pathological signature for this condition, and the lack of healthcare provider access to "indicative biomarkers" that are either unavailable at community clinics or costly due to lack of insurance coverage. The role of resting state function MRI (rs-fMRI) as a diagnostic biomarker has been underexplored in this disease. We propose using a novel cloud-based automated imaging software processing program that identifies abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI) and data from the Human Connectome Project (HCP). Furthermore, the imaging protocol to capture this data is relatively short (15 minutes) and can be performed at most imaging centers, lending potential clinical applicability to this study. We intend to study dysfunctional large scale brain networks (LSBNs) in DLB by comparing rs-fMRI imaging data in this population with cognitively normal (CN) and mild Alzheimer's disease (AD) subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI)-2/3 database.

Interventions

  • PROCEDURE Infinitome

Trial Details

FieldValue
Enrollment Target 91 participants
Start Date 2021-04-27
Est. Completion 2023-06-19

Sponsor

HealthPartners Institute

146 total trials

What the Registry Record Tells You About NCT04773041

The ClinicalTrials.gov registry entry for NCT04773041 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Infinitome is the first listed.

NCT04773041 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04773041 about?

NCT04773041 is a clinical study titled "Dementia With Lewy Bodies - Infinitome". Dementia with Lewy bodies (DLB) is the second most common cause of dementia and is associated with parkinsonism, hallucinations, and cognitive fluctuations. Diagnosis is often either missed or delayed due to physician lack of familiarity with characteristic features, the inability of structural MRI ...

What is the current status of trial NCT04773041?

This trial is currently completed. The enrollment target is 91 participants. The study started on 2021-04-27. Estimated completion is 2023-06-19.

What interventions are being tested in trial NCT04773041?

The interventions under investigation include: Infinitome (PROCEDURE).

Who is sponsoring clinical trial NCT04773041?

This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.